The Delhi High Court has upheld the KIND brand owned by Mankind Pharma, a leading pharmaceutical company in India, and quashed the opposition to its trademark KINDPAN. This decision has significant implications for the pharmaceutical industry and intellectual property (IP) law in India.

Mankind Pharma had filed for the trademark KINDPAN in 2019, but it was opposed by a rival company, Otsuka Pharmaceutical Company, which claimed that the trademark was similar to its own brand name “Kindly” and could cause confusion among consumers. Otsuka also argued that Mankind Pharma’s application was not in good faith and was an attempt to capitalise on the reputation of Otsuka’s brand.

However, the Delhi High Court has dismissed Otsuka’s opposition and upheld Mankind Pharma’s trademark application. The court observed that the trademarks KINDPAN and Kindly are distinct and the similarity between the two marks is limited only to the prefix “Kind”, which is a common prefix in several trademarks. The court also noted that Mankind Pharma had filed for the trademark KINDPAN in good faith and had not attempted to deceive or mislead consumers.

This judgment is significant for several reasons. Firstly, it establishes that a company can own multiple trademarks with similar prefixes, provided that the marks are distinct and do not cause confusion among consumers. Secondly, it shows that a company’s reputation and goodwill are not transferable to another company, and that each trademark application must be evaluated on its own merit.

The judgment also highlights the importance of clear and precise language in trademark applications. The Delhi High Court emphasized that the similarity between the trademarks KINDPAN and Kindly was limited to the prefix “Kind” and that the marks were not so similar as to cause confusion among consumers.

Overall, this judgment is a positive development for the pharmaceutical industry and IP law in India. It provides a clear framework for trademark applications and oppositions, and helps to ensure that companies can protect their intellectual property rights without undue interference from rival companies.

The Delhi High Court has ruled in favor of Mankind Pharma Limited, ordering the removal of a similar trademark “Kindpan” registered by a proprietorship firm, Sanavita Medicare. Mankind Pharma claimed that it was the owner of the “Kind” and “Mankind” marks, and that the respondent’s registration of the “Kind” mark in class 5 for medicinal and pharmaceutical preparations was an attempt to capitalize on Mankind Pharma’s goodwill and reputation.

The court agreed with Mankind Pharma’s argument, noting that Mankind Pharma was the owner and prior user of the “Kind” and “Mankind” marks, and that the respondent had no plausible reason for adopting the impugned mark. The court observed that the respondent’s application for registration of the impugned mark on a “proposed to be used” basis was suspicious, and that the only reason for doing so was to exploit Mankind Pharma’s established goodwill and built-up reputation.

The court also noted that Mankind Pharma had developed a strong reputation and goodwill in the “Mankind” and “Kind” family of marks, and that the impugned mark was likely to cause confusion among customers. Therefore, the court directed the Trademarks Registry to remove the impugned trademark, citing that it was liable to be taken off due to its similarity to Mankind Pharma’s existing marks.

This decision serves as a reminder of the importance of trademark protection and the need for businesses to vigilantly monitor and protect their intellectual property rights. It also highlights the court’s willingness to take action against trademark infringement and to protect the interests of established businesses.

Here is a summary of the content in 400 words:

Mankind Pharma, a pharmaceutical company, has launched a new campaign for its 100% vegetarian multivitamin tablets, HealthOK, featuring actress and strict vegetarian Archana Puran Singh. The campaign highlights the common dilemma among vegetarians of unintentionally consuming non-vegetarian supplements. Archana Puran Singh plays the role of a protagonist on a mission to find a “hidden non-vegetarian” at a family function, which leads her to Jijaji, who unknowingly consumes a non-vegetarian multivitamin. This relatable scenario showcases the reality that many vegetarians consume non-vegetarian supplements without realizing it.

The HealthOK multivitamin tablets are positioned as the ideal solution, with Taurine and Ginseng providing sustained energy and supporting fitness and overall well-being. The campaign targets a large vegetarian population across several Indian states, particularly during the Navratri festivities, when millions of Indians follow a vegetarian diet. The campaign aims to raise awareness about the importance of taking HealthOK tablets, which are exclusively sourced from vegetarian ingredients.

Mankind Pharma’s Vice President, Joy Chatterjee, emphasized the importance of the campaign, stating that HealthOK tablets cater to the specific needs of the vegetarian male population and align with their commitment to a vegetarian lifestyle. Archana Puran Singh expressed her excitement about the campaign, highlighting the importance of promoting a vegetarian multivitamin that vegetarians can consume with confidence.

The campaign will be launched across TV, digital, and social media platforms to maximize reach and awareness. With its humorous yet insightful approach, Mankind Pharma aims to make HealthOK the go-to multivitamin for vegetarians looking for a high-quality, nutritional supplement that aligns with their dietary values.

Mankind Pharma, India’s fourth-largest pharmaceutical company, has launched a new campaign for its HealthOK 100% vegetarian multivitamin tablets, featuring actress Archana Puran Singh. The campaign is aimed at raising awareness about the brand’s 100% vegetarian multivitamin tablets, which provide complete nutritional support while aligning with Indian vegetarian’s dietary practices. The campaign humorously depicts Archana’s quest to find a non-vegetarian multivitamin in an Indian vegetarian family function, highlighting the gap between the need for multivitamins and the lack of vegetarian options.

India has a significant vegetarian population, particularly in states like Rajasthan, Uttar Pradesh, Maharashtra, Gujarat, and Delhi NCR, where many follow a strict vegetarian diet. However, many vegetarians unknowingly consume non-vegetarian multivitamin supplements, which conflicts with their lifestyle. HealthOK tablets address this concern by offering 100% vegetarian multivitamin tablets, enriched with Taurine and Ginseng, providing essential nutrients without compromising on dietary preferences.

The campaign, which will be launched across various platforms, coincides with the Navratri festivities, a time when many Indians embrace vegetarianism as part of their religious observance. Archana Puran Singh, who is a strict vegetarian herself, has expressed her enthusiasm about the campaign, stating that it is crucial for vegetarians to be aware of the HealthOK vegetarian nutritional supplement being available, which they can consume. The campaign aims to create strong awareness about HealthOK as the preferred choice for vegetarians seeking a high-quality multivitamin solution.

Here is a 400-word summary of the content:

Mankind Pharma, a leading player in the pharmaceutical industry, has successfully completed the amalgamation of three companies: Shree Jee Laboratory Private Limited, JPR Labs Private Limited, and Jaspack Industries Private Limited. As of March 29, the three companies have been consolidated into Mankind Pharma, expanding the company’s presence and capabilities in the industry.

This strategic move is expected to bring significant benefits to Mankind Pharma, including increased financial resources, enhanced research and development capabilities, and a wider range of products and services. The amalgamation will also provide the company with a stronger foothold in the market, enabling it to better cater to the needs of its customers and stakeholders.

Shree Jee Laboratory is a well-established company with a significant presence in the Indian pharmaceutical market, known for its high-quality products and commitment to innovation. JPR Labs, on the other hand, is a leading manufacturer of pharmaceuticals, APIs, and other products, with a strong presence in the domestic and international markets. Jaspack Industries is a prominent company in the field of pharmaceutical packaging and specialty chemicals.

The amalgamation of these three companies into Mankind Pharma is expected to create a strong and competitive player in the industry, with a wider range of products and services to offer. This will ultimately benefit the company’s customers, who will have access to a broader portfolio of products and services.

Here is a summary of the content in 400 words:

Mankind Pharma, a pharmaceutical company, has received tax demand orders from the Income Tax Department for Assessment Years (AY) 2014-15 to 2017-18, totalling ₹183.11 crore, including interest. The demand arises from the disallowance of various expenditures under Section 37(1) of the Income-tax Act, 1961. The orders were issued by the Office of the Deputy Commissioner of Income Tax, Central Circle 29, New Delhi, and were received by the company through the IT portal on March 28, 2025.

Mankind Pharma has stated that it believes the tax demand is not legally justified and that it has strong factual and legal grounds to challenge the order. The company is planning to appeal the order under applicable laws. Despite the demand, Mankind Pharma believes that the order will not have any material impact on its financials or operations.

The company’s position on the tax demand is likely to be closely monitored by investors, who will be watching to see how the company navigates this challenge. The dispute highlights the potential risks and complexities associated with tax compliance and the need for companies to have robust tax planning and litigation strategies in place to mitigate such risks.

In summary, Mankind Pharma has received tax demand orders from the Income Tax Department for Assessment Years 2014-15 to 2017-18, totalling ₹183.11 crore, including interest. The company believes the demand is not legally justified and plans to appeal the order under applicable laws. The situation will be closely monitored by investors as the company navigates this tax challenge.

Mankind Pharma is an Indian pharmaceutical company that develops, manufactures, and markets a diverse range of pharmaceutical formulations and consumer healthcare products. The company’s portfolio includes a broad spectrum of treatments for various therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neurology, vitamins, minerals, and respiratory health.

The company’s product range is vast, with over 200 products, including prescription and over-the-counter (OTC) branded products. Its portfolio of brands covers women’s health, fertility, and critical care, with multiple brands present in each therapy area. Some of its notable brands include Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, and Dynaglipt, among others.

Mankind Pharma has a strong presence in the Indian market, with several subsidiaries, including Lifestar Pharma Private Limited, Magnet Labs Private Limited, and Jaspack Industries Private Limited, to name a few. The company’s portfolio is constantly evolving, with a focus on innovation, quality, and reliability, to provide effective and affordable healthcare solutions to its customers. With a wide range of products and a strong distribution network, Mankind Pharma is a significant player in the Indian pharmaceutical industry.

Mankind Pharma, a leading pharmaceutical company in India, has reportedly received approval from the Central Drugs Standard Control Organization (CDSCO) panel for conducting a bioequivalence study of its Resmetirom Tablets. This development is significant for the company as it paves the way for the launch of a generic version of the branded drug in the Indian market.

The bioequivalence study is a critical step in the approval process for generic drugs, which involves comparing the pharmacokinetic and pharmacodynamic properties of the generic product with those of the branded product. The CDSCO panel’s approval indicates that Mankind Pharma’s Resmetirom Tablets have demonstrated comparable bioavailability, pharmacokinetics, and efficacy to the branded drug.

Resmetirom is a marketed branded product for the treatment of certain types of anemia, and its generic version is expected to provide an affordable alternative to patients. The Indian pharmaceutical market, one of the largest in the world, is often referred to as the “pharmacy of the world” due to its large population and significant demand for medicines.

The approval of the bioequivalence study is a testament to Mankind Pharma’s commitment to quality and research, as well as its ability to develop high-quality generic drugs that meet international standards. With this approval, the company can now proceed with the launch of its generic Resmetirom Tablets, which is expected to benefit patients who require this treatment.

The approval also demonstrates the CDSCO’s commitment to fostering a competitive and innovative pharmaceutical industry in India. The organization’s efforts to streamline the approval process and facilitate the development of generic drugs are expected to lead to increased access to affordable medicines for patients in India and other countries.

Overall, the approval of the bioequivalence study for Mankind Pharma’s Resmetirom Tablets is a significant development in the Indian pharmaceutical industry, marking a step towards making high-quality generic drugs more accessible to patients. With its commitment to research and development, Mankind Pharma is well-positioned to continue making a positive impact on the healthcare landscape in India and beyond.